.jetcityimage/iStock Content via Getty Images Morgan Stanley has actually selected Eli Lilly (NYSE: LLY) as its leading biopharma selection for 2025 and also rated an additional 9 names in the room as obese. The expenditure financial institution stated in a details that it remains to think “diabesity is set to come to be.